The baby's body works desperately hard to breathe
Antes mesmo de nascer, um bebê pode receber sua primeira proteção contra uma das principais causas de internação infantil no Brasil. O Sistema Único de Saúde oferece às gestantes uma vacina contra o vírus sincicial respiratório — o agente por trás da bronquiolite —, permitindo que anticorpos maternos atravessem a placenta e blindem o recém-nascido nos meses mais vulneráveis de sua vida. É uma estratégia que reconhece uma verdade antiga da medicina: às vezes, o melhor momento para proteger uma criança é antes que ela chegue ao mundo.
- O VSR transforma uma tosse comum em emergência respiratória para bebês, cujas vias aéreas estreitas podem ser bloqueadas com facilidade pela inflamação e pelo muco — em casos graves, a criança precisa de intubação para sobreviver.
- A doença é responsável por 80% dos casos de bronquiolite e cerca de 40% das pneumonias em crianças menores de dois anos, tornando-se a principal razão de internações nessa faixa etária.
- A vacina aplicada entre a 32ª e a 36ª semana de gestação transfere anticorpos ao feto via placenta, reduzindo drasticamente o risco de formas graves da doença nos primeiros meses de vida.
- Sorocaba já atingiu 83,44% de cobertura vacinal entre gestantes e registrou queda de 46 para 11 casos de VSR em bebês menores de um ano entre 2025 e 2026 — um sinal de que a estratégia está funcionando.
- Para os mais vulneráveis — prematuros e crianças com condições de saúde preexistentes —, o município disponibiliza também o nirsevimabe, anticorpo monoclonal aplicado por agendamento nas unidades de referência.
Um vírus que envia milhares de bebês ao hospital a cada ano agora encontra resistência antes mesmo do nascimento. O SUS passou a oferecer gratuitamente às gestantes a vacina contra o vírus sincicial respiratório, o VSR — principal responsável pela bronquiolite, infecção que estreita as vias aéreas dos bebês e pode transformar uma tosse simples em risco de vida.
A bronquiolite é uma das principais causas de internação infantil no país. O que torna o VSR especialmente perigoso em recém-nascidos é a geometria do próprio corpo: vias aéreas mais estreitas significam que qualquer inflamação pode comprometer gravemente a respiração. Nos casos mais severos, a criança precisa de oxigênio suplementar, internação ou até intubação. O vírus também pode abrir caminho para pneumonias bacterianas secundárias. Segundo análises médicas, o VSR responde por cerca de 80% dos casos de bronquiolite e aproximadamente 40% das pneumonias em crianças menores de dois anos.
A lógica da estratégia é precisa: vacinar a mãe durante a gestação para que seus anticorpos atravessem a placenta e protejam o bebê. A dose única é aplicada entre a 32ª e a 36ª semana, com pelo menos 14 dias de antecedência ao parto para garantir a transferência adequada. A vacina não impede totalmente a infecção, mas reduz significativamente o risco de doença grave — um bebê protegido pode desenvolver apenas um resfriado comum no lugar de uma crise respiratória severa.
Em Sorocaba, a vacina está disponível nas 33 unidades básicas de saúde do município, com cobertura de 83,44% entre as gestantes atendidas pelo sistema público. Os resultados já aparecem nos dados: em 2025, foram registrados 46 casos de VSR em bebês menores de um ano; em 2026, esse número caiu para 11, sem mortes em nenhum dos dois anos. Para prematuros e crianças com condições de saúde preexistentes, o município também disponibiliza o nirsevimabe, anticorpo monoclonal aplicado por agendamento. Quanto mais gestantes forem imunizadas, maior o escudo coletivo ao redor dos recém-nascidos nos meses em que são mais frágeis.
A respiratory virus that sends thousands of babies to the hospital each year now has a prevention strategy that begins before birth. Brazil's public health system is offering pregnant women a vaccine against respiratory syncytial virus, or VSR, the pathogen responsible for bronchiolitis—an infection that narrows the airways of infants and can turn a simple cough into a life-threatening emergency.
Bronchiolitis ranks among the leading reasons infants and young children are admitted to hospitals. The disease attacks the respiratory tract, and in the vast majority of cases, VSR is the culprit. What makes this virus particularly dangerous in newborns is the simple geometry of their bodies: their airways are narrower than those of older children and adults. When the virus causes inflammation and mucus buildup, even a small obstruction can severely restrict airflow. The body compensates by forcing the lungs to work harder, pulling in the chest and neck muscles to draw breath. In severe cases, this respiratory distress escalates to the point where children need supplemental oxygen or hospitalization. Some require intubation. VSR can also trigger viral pneumonia and create openings for secondary bacterial infections.
Pediatrician Daniela Barbieri, who has worked in a hospital specializing in severe pediatric cases, has seen firsthand how quickly the disease can deteriorate. She recalls patients arriving with significant respiratory compromise, many already approaching the threshold where mechanical ventilation becomes necessary. According to her analysis, VSR accounts for roughly 80 percent of bronchiolitis cases. The Ministry of Health reports that the virus is tied to about 75 percent of bronchiolitis diagnoses and approximately 40 percent of pneumonias in children under two years old. The vulnerability is greatest in the first months of life, when infants' immune systems are still developing and many have not yet completed their vaccination schedules.
The SUS strategy is elegant in its timing: vaccinate the mother during pregnancy so that her body produces antibodies that cross the placenta and protect the newborn. The vaccine is administered as a single dose between the 32nd and 36th week of gestation, with the requirement that it be given at least 14 days before delivery to allow sufficient antibody transfer. Barbieri emphasizes that the vaccine is safe for both mother and child. It does not prevent infection entirely, but it substantially reduces the risk of severe disease. A vaccinated infant exposed to VSR may develop nothing more than a common cold rather than the gasping, struggling illness that can lead to hospitalization.
In Sorocaba, the vaccine is available at all 33 basic health units across the municipality. As of the latest reporting, 83.44 percent of pregnant women receiving care through the public system have been vaccinated. The city has also received 388 doses of nirsevimab, a monoclonal antibody designed for premature infants born before 37 weeks and for children under two with underlying health conditions. These doses are administered by appointment at the reference health unit.
The numbers suggest the strategy is working. In 2025, Sorocaba recorded 46 cases of VSR in children under one year. In 2026, through the time of this report, that number had fallen to 11. There have been no deaths linked to the virus in either year. Barbieri sees the vaccine as a crucial tool for expanding protection in the earliest and most vulnerable period of life. She notes that many pregnant women are now being counseled to get vaccinated, particularly because the vaccine is free through the public system. The more women who receive protection during pregnancy, she argues, the greater the shield around newborns in those critical first months when the smallest respiratory tract can become a barrier to survival.
Citações Notáveis
The child can come into contact with the virus, but will already have antibodies to fight it. Often the disease manifests only as a common cold, preventing hospitalizations and serious complications.— Pediatrician Daniela Barbieri
The more women who receive the vaccine during pregnancy, the greater the protection of babies in their first months of life.— Pediatrician Daniela Barbieri
A Conversa do Hearth Outra perspectiva sobre a história
Why does this virus hit babies so much harder than older children?
It's about the size of their airways. A newborn's respiratory passages are narrow to begin with, and when VSR causes swelling and mucus, even a small amount of blockage cuts off the oxygen exchange. Their bodies aren't equipped yet to handle that kind of obstruction.
So the vaccine doesn't stop the virus from infecting the baby at all?
No, it doesn't. But it arms the baby with antibodies from the mother. If the virus does get in, the baby's immune system recognizes it and fights back before it becomes severe. Often it just looks like a cold.
Why give it to the mother instead of the baby after birth?
Timing. The first months of life are when complications are worst, and newborns can't be vaccinated yet. By vaccinating the mother in the third trimester, the antibodies cross the placenta naturally. The baby is protected from day one.
What happens if a baby gets severe bronchiolitis?
The inflammation narrows the airways so much that breathing becomes a crisis. The baby's body works desperately hard—you see the chest caving in, the neck straining. Some need oxygen support. In the worst cases, they need to be intubated. It's frightening to watch.
How many babies in Sorocaba are actually getting this protection?
About 83 percent of pregnant women in the public system are being vaccinated. That's substantial coverage. Last year there were 46 cases of VSR in infants under one year in the city. This year, so far, it's 11. No deaths either year.
Is the vaccine new?
It's new to Brazil's public system. The strategy of vaccinating pregnant women to protect newborns is sound—it's how we've protected against other diseases. But for VSR specifically, this is a recent addition to what the health system offers.